Status:
UNKNOWN
Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma
Lead Sponsor:
Ospedale Santa Croce-Carle Cuneo
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
16-80 years
Brief Summary
Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin), bleomycin, vinblastine and d...
Eligibility Criteria
Inclusion
- Patients with advanced Hodgkin's lymphoma according to the World Health Organization classification
- Age 16-80
- Not previously treated
- Stage IIB to IVB or stage IIA with adverse prognostic factors (more than 3 nodal sites, ESR \> 50 mm, bulky lesion)
- Written informed consent
Exclusion
- Patients aged more than 80
- Concomitant or previously treated neoplastic disorder less than 5 years before the diagnosis of Hodgkin's lymphoma
- Psychiatric disorders
- Uncontrolled infectious disease
- Impaired cardiac (EF \< 50%) or renal (creatinine clearance \< 60 ml/m)function
- Pregnancy and lactation
- Uncompensated diabetes mellitus and fasting glucose levels over 200 mg/dl
Key Trial Info
Start Date :
January 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00877747
Start Date
January 1 2006
End Date
October 1 2015
Last Update
October 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Santa Croce e Carle
Cuneo, Italy, 12100